1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AbiVax’s Partnering Prospects For MicroRNA-based Drug Boosted By Rheumatoid Arthritis Data

Phase IIa RA Results Build On Ulcerative Colitis Promise

 
• By Sten Stovall

Now that AbiVax's novel anti-inflammatory ABX464 has demonstrated solid safety and efficacy in rheumatoid arthritis and ulcerative colitis, the French biotech is exploring additional programs in chronic inflammatory indications – and looking for a partner.

AbiVax reported excellent Phase IIa Clinical Safety And Efficacy Results in RA With 50mg ABX464 • Source: Alamy

Abivax S.A.’s lead investigational therapy, ABX464, has shown proof-of-concept Phase IIa trial for rheumatoid arthritis in impressive style, building on the first-in-class anti-inflammatory’s robust performance last month in a Phase IIb study for ulcerative colitis and, the French biotech hopes, putting it in a stronger negotiating position for eventually partnering the product.

AbiVax’s management, led by CEO Hartmut Erlich, made the comments to analysts on 23 June when outlining positive topline Phase IIa results from a trial assessing ABX464 in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis (RA) in patients with either

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.